Inja Waldhauer

USPTO Granted Patents = 10 (Patent Applications = 5)

CIPO Patents = 2

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 9.2

ph-index = 3

Forward Citations = 43(Granted Patents)

Location History:

Urdorf, CH (2016 - 2023)
Schlieren, CH (2022 - 2024)

Company Filing History:

7 out of 4,942

Hoffmann-la Roche Inc.

Years Active: 2016-2025

where 'Filed Patents' based on already Granted Patents

10 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12215155 - Antibodies binding to CD3 and CD19 (2025-02-04),

2. 12023368 - Immunoconjugates (2024-07-02),

3. 11827711 - Antibodies binding to NKG2D (2023-11-28),

4. 11780920 - Antibodies binding to CD3 and CD19 (2023-10-10),

5. 11672858 - Bispecific antibody molecules binding to CD3 and TYRP-1 (2023-06-13),

6. 11591397 - Bispecific antibody molecules binding to CD3 and EGFRvIII (2023-02-28),

7. 11413331 - Immunoconjugates (2022-08-16),

8. 11214622 - Antibodies specific for DR5 and methods of use (2022-01-04),

9. 9926379 - Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 (2018-03-27),

10. 9481730 - DR5—FAP bispecific death receptor agonistic antibodies (2016-11-01),

Title: Inja Waldhauer: Innovator in Antibody Research

Introduction

Inja Waldhauer is a prominent inventor based in Urdorf, Switzerland. She has made significant contributions to the field of biotechnology, particularly in the development of innovative antibodies. With a total of 10 patents to her name, Waldhauer's work has the potential to impact various therapeutic applications.

Latest Patents

Waldhauer's latest patents include groundbreaking inventions such as antibodies binding to CD3 and CD19. This invention relates to antibodies that activate T cells, along with polynucleotides encoding these antibodies, and methods for their production and use in treating diseases. Another notable patent involves immunoconjugates, specifically those comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. This invention also includes polynucleotide molecules encoding the immunoconjugates, as well as methods for their production and pharmaceutical applications.

Career Highlights

Throughout her career, Inja Waldhauer has worked with leading companies in the biotechnology sector, including Hoffmann-La Roche Inc. and Roche Glycart AG. Her experience in these organizations has allowed her to refine her expertise in antibody development and therapeutic applications.

Collaborations

Waldhauer has collaborated with notable professionals in her field, including Ekkehard Moessner and Ralf Hosse. These collaborations have further enhanced her research and innovation capabilities.

Conclusion

Inja Waldhauer is a distinguished inventor whose work in antibody research is paving the way for new therapeutic solutions. Her contributions to the field are significant and continue to influence advancements in biotechnology.

This text is generated by artificial intelligence and may not be accurate.